Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients ...

Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic branded formulation ...

A brand new candidate for weight-loss treatment is on the table, with scientists uncovering for the first time how a hormone ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

Major heart health risk factors like obesity, diabetes and high blood pressure remain on the rise in the United States, ...

A commission proposed a new definition of obesity focused on how excess fat affects the body, rather than assessing body mass ...